$STIM

Chernett Jorey purchased $62K of STIM

Chernett Jorey purchased 35,000 shares of Neuronetics, Inc. (STIM) at $1.78 on 2026-07-14.

Original reporting
SEC EDGAR · Chernett Jorey
Published Jul 15, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STIM
Bullish
medium confidence
Mentioned
$STIM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STIMBullishLow
01

Why it matters

A 10% owner purchased 35,000 shares at $1.7800, totaling $62,300, with holdings after the trade of 10,588,988 shares.

02

Market read

Traders may view the buy as a modest sentiment input, but there is no new operational or financial information.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide any 10b5-1 plan context (it says none), limiting inference about intent.

Relevance 4/10Novelty 3/10Timing: new Form 4 filed 2026-07-15, covering a 2026-07-14 purchase

Background

This is an SEC Form 4 insider transaction disclosure for Neuronetics, Inc. (STIM).

Company-level read

Ticker impact

$STIMBullishMedium confidence
Context

Neuronetics insider Chernett Jorey, a 10% owner, bought 35,000 shares at $1.7800 on 2026-07-14 via open-market purchase.

Expected impact

Likely limited near-term impact; may modestly support sentiment if traders treat it as a confidence signal.

Evidence & confidence

Form 4 insider buys can influence sentiment, but this article provides no accompanying guidance, operational update, or material corporate event.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification activity and may not reflect near-term business improvement.

Key entities

  • Neuronetics, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Chernett Jorey

    10% owner who executed an open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STIMMedAI 8/10

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

Med

Neuronetics, Inc. Q2 2026 Earnings Call Summary

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

$STIMMedAI 8/10

Neuronetics Q2 Earnings Call Highlights

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.